Astrazeneca Plc $AZN Stock Holdings Trimmed by OLD National Bancorp IN

OLD National Bancorp IN lessened its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 57.6% in the first quarter, according to its most recent filing with the SEC. The firm owned 5,196 shares of the company’s stock after selling 7,061 shares during the quarter. OLD National Bancorp IN’s holdings in Astrazeneca were worth $1,025,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Davidson Trust Co. bought a new position in shares of Astrazeneca in the first quarter valued at approximately $208,000. Meyer Handelman Co. acquired a new stake in Astrazeneca in the first quarter worth approximately $386,000. Cardinal Point Capital Management ULC acquired a new stake in Astrazeneca in the first quarter worth approximately $239,000. Tanager Wealth Management LLP bought a new position in Astrazeneca during the 1st quarter valued at $260,000. Finally, MBM Wealth Consultants LLC acquired a new position in shares of Astrazeneca during the 1st quarter valued at $83,000. Institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Barclays reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Weiss Ratings cut Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday. Finally, Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Stock Performance

Shares of AZN stock opened at $188.58 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The stock’s 50-day moving average is $184.66 and its two-hundred day moving average is $187.05. The firm has a market cap of $292.47 billion, a P/E ratio of 28.32, a PEG ratio of 1.64 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Analysts predict that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.